Drug Trial Radar · NCT05919069
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Jun 16, 2023
Primary completion
Sep 16, 2024
Study completion Sep 16, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
Conditions
- Hepatic Impairment
Interventions
AZD2693Drug
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameters AUCinfTime frame: 85 days
- PK parameters AUClastTime frame: 85 days
- PK parameters CmaxTime frame: 85 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Rialto, California
Research Site
Miami Lakes, Florida
Research Site
Orlando, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.